What 20/20 Biolabs Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 34,564 |
| Disposed | 0 | 0 |
| Net activity | +0 | +34,564 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Cohen Richard M | Director | Feb 19 | Derivative Conversion · C | +7,700 | — | — | 7,700 |
| Rollins John Woodson | Director | Feb 19 | Derivative Conversion · C | +6,135 | — | — | 30,275 |
| Rollins John Woodson | Director | Feb 19 | Derivative Conversion · C | +13,029 | — | — | 24,140 |
| Ross Michael A. | Director | Feb 19 | Derivative Conversion · C | +31 | — | — | 31 |
| Compton John G. | Director | Feb 19 | Derivative Conversion · C | +7,669 | — | — | 14,335 |
Loading...
